home / stock / lixt / lixt quote
Last: | $3.74 |
---|---|
Change Percent: | 0.0% |
Open: | $4 |
Close: | $3.74 |
High: | $4.125 |
Low: | $3.7 |
Volume: | 106,267 |
Last Trade Date Time: | 11/26/2020 04:55:13 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.74 | $4 | $3.74 | $4.125 | $3.7 | 106,267 | 11-26-2020 |
$3.74 | $4 | $3.74 | $4.125 | $3.7 | 104,566 | 11-25-2020 |
$0.98 | $0.99 | $0.98 | $1 | $0.795 | 11,473 | 11-19-2020 |
$0.9498 | $1.1 | $0.9498 | $1.1 | $0.79 | 29,614 | 11-18-2020 |
$0.8999 | $1.1 | $0.8999 | $1.1 | $0.82 | 23,839 | 11-17-2020 |
$0.95 | $1.14 | $0.95 | $1.14 | $0.9001 | 7,206 | 11-16-2020 |
$1.13 | $0.9001 | $1.13 | $1.13 | $0.9001 | 1,491 | 11-13-2020 |
$1.13 | $1.13 | $1.13 | $1.13 | $1.13 | 210 | 11-12-2020 |
$1.13 | $1.13 | $1.13 | $1.13 | $1.13 | 4,000 | 11-11-2020 |
$1.14 | $1.14 | $1.14 | $1.14 | $1.14 | 349 | 11-06-2020 |
$1.14 | $1.05 | $1.14 | $1.14 | $1.05 | 1,338 | 11-05-2020 |
$1.05 | $1 | $1.05 | $1.05 | $1 | 291 | 11-04-2020 |
$1 | $0.9 | $1 | $1 | $0.9 | 8,218 | 11-02-2020 |
$1.12 | $1.12 | $1.12 | $1.12 | $1.12 | 1,014 | 10-27-2020 |
$1.16 | $1.16 | $1.16 | $1.16 | $1.16 | 601 | 10-22-2020 |
$1.16 | $1.16 | $1.16 | $1.16 | $1.16 | 320 | 10-21-2020 |
$1.16 | $1.16 | $1.16 | $1.16 | $1.05 | 2,111 | 10-20-2020 |
$1.16 | $1.16 | $1.16 | $1.16 | $1.16 | 100 | 10-19-2020 |
$1.17 | $1.15 | $1.17 | $1.17 | $1.01 | 360 | 10-15-2020 |
$1.15 | $1.05 | $1.15 | $1.15 | $1.05 | 319 | 10-13-2020 |
News, Short Squeeze, Breakout and More Instantly...
Lixte Biotechnology Holdings Inc. Company Name:
LIXT Stock Symbol:
OTCMKTS Market:
Lixte Biotechnology Holdings Inc. Website:
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ...
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( ...